312 related articles for article (PubMed ID: 10023767)
1. An antiviral mechanism of nitric oxide: inhibition of a viral protease.
Saura M; Zaragoza C; McMillan A; Quick RA; Hohenadl C; Lowenstein JM; Lowenstein CJ
Immunity; 1999 Jan; 10(1):21-8. PubMed ID: 10023767
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
Ramajayam R; Tan KP; Liu HG; Liang PH
Bioorg Med Chem; 2010 Nov; 18(22):7849-54. PubMed ID: 20947359
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy.
Badorff C; Fichtlscherer B; Rhoads RE; Zeiher AM; Muelsch A; Dimmeler S; Knowlton KU
Circulation; 2000 Oct; 102(18):2276-81. PubMed ID: 11056105
[TBL] [Abstract][Full Text] [Related]
4. N-Terminomics TAILS Identifies Host Cell Substrates of Poliovirus and Coxsackievirus B3 3C Proteinases That Modulate Virus Infection.
Jagdeo JM; Dufour A; Klein T; Solis N; Kleifeld O; Kizhakkedathu J; Luo H; Overall CM; Jan E
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437971
[TBL] [Abstract][Full Text] [Related]
5. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114
[TBL] [Abstract][Full Text] [Related]
6. Human rhinovirus 3C protease as a potential target for the development of antiviral agents.
Wanga QM; Chen SH
Curr Protein Pept Sci; 2007 Feb; 8(1):19-27. PubMed ID: 17305557
[TBL] [Abstract][Full Text] [Related]
7. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.
Patick AK; Binford SL; Brothers MA; Jackson RL; Ford CE; Diem MD; Maldonado F; Dragovich PS; Zhou R; Prins TJ; Fuhrman SA; Meador JW; Zalman LS; Matthews DA; Worland ST
Antimicrob Agents Chemother; 1999 Oct; 43(10):2444-50. PubMed ID: 10508022
[TBL] [Abstract][Full Text] [Related]
8. Essential Role of Enterovirus 2A Protease in Counteracting Stress Granule Formation and the Induction of Type I Interferon.
Visser LJ; Langereis MA; Rabouw HH; Wahedi M; Muntjewerff EM; de Groot RJ; van Kuppeveld FJM
J Virol; 2019 May; 93(10):. PubMed ID: 30867299
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.
Im I; Lee ES; Choi SJ; Lee JY; Kim YC
Bioorg Med Chem Lett; 2009 Jul; 19(13):3632-6. PubMed ID: 19464175
[TBL] [Abstract][Full Text] [Related]
10. Polyamine Analog Diethylnorspermidine Restricts Coxsackievirus B3 and Is Overcome by 2A Protease Mutation In Vitro.
Hulsebosch BM; Mounce BC
Viruses; 2021 Feb; 13(2):. PubMed ID: 33669273
[TBL] [Abstract][Full Text] [Related]
11. FUS/TLS Suppresses Enterovirus Replication and Promotes Antiviral Innate Immune Responses.
Xue YC; Ng CS; Mohamud Y; Fung G; Liu H; Bahreyni A; Zhang J; Luo H
J Virol; 2021 May; 95(12):. PubMed ID: 33827951
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses.
Meng B; Lan K; Xie J; Lerner RA; Wilson IA; Yang B
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13499-13508. PubMed ID: 32467165
[TBL] [Abstract][Full Text] [Related]
13. 2,3,4-Trihydroxybenzyl-hydrazide analogues as novel potent coxsackievirus B3 3C protease inhibitors.
Kim BK; Ko H; Jeon ES; Ju ES; Jeong LS; Kim YC
Eur J Med Chem; 2016 Sep; 120():202-16. PubMed ID: 27191615
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice.
Zell R; Markgraf R; Schmidtke M; Görlach M; Stelzner A; Henke A; Sigusch HH; Glück B
Med Microbiol Immunol; 2004 May; 193(2-3):91-100. PubMed ID: 14513374
[TBL] [Abstract][Full Text] [Related]
15. A Novel Enterovirus 71 (EV71) Virulence Determinant: The 69th Residue of 3C Protease Modulates Pathogenicity.
Li B; Yue Y; Zhang Y; Yuan Z; Li P; Song N; Lin W; Liu Y; Gu L; Meng H
Front Cell Infect Microbiol; 2017; 7():26. PubMed ID: 28217559
[TBL] [Abstract][Full Text] [Related]
16. Non-covalent inhibitors of rhinovirus 3C protease.
Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N
Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345
[TBL] [Abstract][Full Text] [Related]
17. New Coxsackievirus 2A
Laitinen OH; Svedin E; Kapell S; Hankaniemi MM; Larsson PG; Domsgen E; Stone VM; Määttä JAE; Hyöty H; Hytönen VP; Flodström-Tullberg M
J Virol Methods; 2018 May; 255():29-37. PubMed ID: 29425680
[TBL] [Abstract][Full Text] [Related]
18. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
19. Roles of the Picornaviral 3C Proteinase in the Viral Life Cycle and Host Cells.
Sun D; Chen S; Cheng A; Wang M
Viruses; 2016 Mar; 8(3):82. PubMed ID: 26999188
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93.
Costenaro L; Kaczmarska Z; Arnan C; Janowski R; Coutard B; Solà M; Gorbalenya AE; Norder H; Canard B; Coll M
J Virol; 2011 Oct; 85(20):10764-73. PubMed ID: 21835784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
